Roy Smythe, SomaLogic

More than 20 years in­to pro­teomics quest, So­ma­Log­ic keeps adding in­vestors as it nears a po­ten­tial pub­lic of­fer­ing

In the world of ven­ture cap­i­tal, in­vestors are con­stant­ly look­ing for the next best thing — but some­times a good idea takes time to de­vel­op. Take So­ma­Log­ic, for ex­am­ple: More than two decades in­to its life, the biotech is bag­ging more and more in­vestor cash —and a pub­lic of­fer­ing could be on the close hori­zon.

A month af­ter clos­ing a $121 mil­lion Se­ries A, pro­teomics-fo­cused So­ma­Log­ic is adding an­oth­er $81 mil­lion to the round — be­com­ing, as CEO Roy Smythe joked, “maybe the on­ly biotech com­pa­ny in the his­to­ry of this in­dus­try that’s hav­ing its Se­ries A at age 21.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.